What Happened?
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 13.6% in the afternoon session after the company provided strong 2026 financial guidance that surpassed analyst expectations.
ANI projected total net revenues for 2026 to be between $1.055 billion and $1.115 billion. This forecast came in well above the FactSet consensus estimate of $955.1 million. A key driver for this expected growth was the company's rare disease treatment, Cortrophin Gel, which was projected to generate between $540 million and $575 million in revenue, a jump of 55% to 65% from 2025. The company also highlighted strong preliminary 2025 results for the drug, with its net revenues growing 76% from the previous year to $347.8 million. To support this momentum, ANI announced plans to expand its rare disease team by about 90 people.
The shares closed the day at $84.43, up 10.7% from previous close.
Is now the time to buy ANI Pharmaceuticals? Access our full analysis report here, it’s free.
What Is The Market Telling Us
ANI Pharmaceuticals’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. Moves this big are rare for ANI Pharmaceuticals and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 5 months ago when the stock gained 18.4% on the news that the company reported second-quarter earnings and revenue that surpassed analyst estimates and raised its full-year financial guidance. The specialty pharmaceutical company announced quarterly net revenues of $211.4 million, a 53.1% year-over-year increase that beat analyst estimates of $191.5 million. Adjusted earnings per share came in at $1.80, also significantly higher than the consensus forecast of $1.42. Bolstering investor confidence, ANI Pharmaceuticals increased its 2025 forecast, now expecting full-year revenues between $818 million and $843 million and adjusted earnings per share from $6.98 to $7.35, both well above prior guidance.
ANI Pharmaceuticals is up 7.7% since the beginning of the year, but at $84.43 per share, it is still trading 14.6% below its 52-week high of $98.81 from September 2025. Investors who bought $1,000 worth of ANI Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $2,642.
While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report, it’s free.